Login
Navigate Fool.com
Will SGEN beat
the market?

Seattle Genetics (NASDAQ: SGEN)

Community Rating: 4 Stars: Favorite

34.94 -0.06 (-0.17%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $35.28
Previous Close $35.00
Daily Range $34.48 - $35.35
52-Week Range $32.35 - $55.99
Market Cap $4.3B
P/E Ratio -70.00
Dividend (Yield) $0.00 (0.0%)
Volume 140,645
Average Daily Volume 1,052,375
Current FY EPS -$0.91

How do you think SGEN
will perform against the market?

Top SGEN Bull/Bear Pitches

 

trackjakeambrose (< 20)
Submitted December 17, 2013

1

0 Replies Reply Report this Post
 

PDTBiotech (< 20)
Submitted July 7, 2011

$2.34B for a drug which treats HL and ALCL seems very, very rich, even when taking SGEN's strong balance sheet into account. Very cool platform, but the target for brentuximab vedotin is expressed on … More

1 Replies Reply Report this Post

News & Commentary

Are Investors Wrong About Celldex Therapeutics?

Short-sellers have been pushing into Celldex Therapeutics this year. Here's why.

4 Top Biotechs Expected to Beat Earnings Expectations

Why Merck Should Buy Inovio, Seattle Genetics, or MannKind

Merck could be gearing up for an acquisition spree. Could Inovio, Seattle Genetics, and MannKind be potential takeover targets?

Seattle Genetics investor and board memeber buys $9 million in stock

Biotech Dilemma: When a Loan Isn't Non-Dilutive

Retrophin takes out a convertible note. As Dendreon has shown, taking on debt can be dangerous if the company can't pay it back. Investors should look for companies like Seattle Genetics and Regeneron Pharmaceuticals that have assets they can sell to slow the cash burn.

Stocks: Insiders Buy at Seattle Genetics, Target, and Emerald Oil

Plus, a purchase at JMP Group.

Seattle Genetics Larger Than S&P 500 Component Patterson Companies

Interesting SGEN Put And Call Options For July 19th

Insider Stock Trading: John Thain Buys Shares at CIT Group; Purchases at Seattle Genetics and Gogo

Plus, an insider buys at Liquid Holdings Group.

Insider Trading: John Thain Buys CIT Group; Purchases at Seattle Genetics and Gogo

Plus, an insider buys at Liquid Holdings Group.

See More SGEN News...

Sector

Healthcare

Industry

Drugs

Seattle Genetics (SGEN) Description

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Website: http://www.seattlegenetics.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks